Review article · 30 Oct 2023
Mini reviewPublished 25 Feb 2022
The function of anti-mesothelin CAR T cells is improved by hairpin RNAs.
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Hematologic malignancies have demonstrated good results with chimeric antigen receptor (CAR) T cell treatment. CAR T cells' antitumor activity, on the other hand, needs to be improved in order to improve therapeutic efficacy in hematologic and solid malignancies. On-target, off-tumor toxicity, antigen escape, short CAR T cell persistence, limited growth, trafficking to the tumour, and T cell activity suppression by an inhibitory tumour microenvironment are all challenges to overcome. Here, we'll look at how genetic engineering can be used to improve the antitumor efficacy of CAR T cell therapy in preclinical animals by refining the design of CAR T cells. The goal of this work was to see how targeted Tim3 knockdown affected the antitumor function of anti-mesothelin (MSLN)-CAR T cells. Three distinct shRNA sequences specific to different regions of the human Tim3 gene were developed and co-inserted into lentiviral vectors with an anti-MSLN-CAR transgene to knock down Tim3 expression. Tim3 expression was measured before and after antigen stimulation to determine the efficiency of Tim3 targeting in T cells. MSLN-CAR T cells and Tim3-targeted MSLN-CAR T cells were then examined for cytotoxic effects, proliferative response, and cytokine production. Tim3 was up-regulated when T cells and MSLN-CAR T cells were activated, according to our findings. In distinct groups of MSLN-CAR T cells, knocking down Tim3 resulted in a considerable reduction in its expression. Tim3 knockdown increased MSLN-CAR T cells' cytotoxic efficacy, cytokine generation, and proliferative ability. Tim3 knockdown increased MSLN-CAR T cells' cytotoxic efficacy, cytokine generation, and proliferative ability. Our findings suggest that inhibiting Tim3 signalling allows tumor-infiltrating CAR T cells that would otherwise be inactivated to continue to grow and perform effector activities, thereby changing the tumour microenvironment from immunosuppressive to immunosupportive.
Subjects
Immunology & MicrobiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Research and Reports in Immunology.
Mini review · 30 Oct 2023
Prevention and therapy for antibody-mediated rejection
Opinion · 28 Oct 2023
Impact of KIR-HLA Class I interaction on kidney transplantation
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalResearch and Reports in Immunology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Stephanie Ryan”
